Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Mobile Mammography Screening as an Opportunity to Increase Access of Rural Women to Breast Cancer Research Studies.

McElfish PA, Su LJ, Lee JY, Runnells G, Henry-Tillman R, Kadlubar SA.

Breast Cancer (Auckl). 2019 Sep 23;13:1178223419876296. doi: 10.1177/1178223419876296. eCollection 2019.

2.

Development and Evaluation of a Blood Glucose Monitoring YouTube Video for Marshallese Patients Using a Community-Based Participatory Research Approach.

McElfish PA, Rowland B, Riklon S, Aitaoto N, Sinclair KA, Ima S, Kadlubar SA, Goulden PA, Hudson JS, Mamis S, Long CR.

Policy Polit Nurs Pract. 2019 Nov;20(4):205-215. doi: 10.1177/1527154419872834. Epub 2019 Sep 19.

PMID:
31537196
3.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S.

Clin Breast Cancer. 2019 Aug;19(4):225-235.e2. doi: 10.1016/j.clbc.2019.02.010. Epub 2019 Mar 6.

PMID:
30928413
4.

Validation of a genetic risk score for Arkansas women of color.

Starlard-Davenport A, Allman R, Dite GS, Hopper JL, Spaeth Tuff E, Macleod S, Kadlubar S, Preston M, Henry-Tillman R.

PLoS One. 2018 Oct 3;13(10):e0204834. doi: 10.1371/journal.pone.0204834. eCollection 2018.

5.

Challenges in recruiting African-American women for a breast cancer genetics study.

Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, Zorn KK.

Hered Cancer Clin Pract. 2018 Apr 24;16:8. doi: 10.1186/s13053-018-0091-3. eCollection 2018.

6.

A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression.

Knox B, Wang Y, Rogers LJ, Xuan J, Yu D, Guan H, Chen J, Shi T, Ning B, Kadlubar SA.

Environ Mol Mutagen. 2018 Mar;59(2):134-143. doi: 10.1002/em.22159. Epub 2017 Dec 5.

7.

Leveraging community-based participatory research capacity to recruit Pacific Islanders into a genetics study.

McElfish PA, Narcisse MR, Long CR, Ayers BL, Hawley NL, Aitaoto N, Riklon S, Su LJ, Ima SZ, Wilmoth RO, Schulz TK, Kadlubar S.

J Community Genet. 2017 Oct;8(4):283-291. doi: 10.1007/s12687-017-0313-9. Epub 2017 Jul 8.

8.

A high frequency missense SULT1B1 allelic variant (L145V) selectively expressed in African descendants exhibits altered kinetic properties.

Tibbs ZE, Guidry AL, Falany JL, Kadlubar SA, Falany CN.

Xenobiotica. 2018 Jan;48(1):79-88. doi: 10.1080/00498254.2017.1282646. Epub 2017 Feb 5.

9.

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.

Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, Lee JY, Orloff MS, Griffin RJ, Henry-Tillman RS, Klimberg S, Hutchins LF, Kadlubar SA.

PLoS One. 2017 Jan 3;12(1):e0168550. doi: 10.1371/journal.pone.0168550. eCollection 2017.

10.

Change in Mammography Use Following the Revised Guidelines from the U.S. Preventive Services Task Force.

Lee JY, Malak SF, Klimberg VS, Henry-Tillman R, Kadlubar S.

Breast J. 2017 Mar;23(2):164-168. doi: 10.1111/tbj.12703. Epub 2016 Oct 31.

PMID:
27797121
11.

2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine (PhIP) induces gene expression changes in JAK/STAT and MAPK pathways related to inflammation, diabetes and cancer.

Rogers LJ, Basnakian AG, Orloff MS, Ning B, Yao-Borengasser A, Raj V, Kadlubar S.

Nutr Metab (Lond). 2016 Aug 20;13:54. doi: 10.1186/s12986-016-0111-0. eCollection 2016.

12.

Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.

Edavana VK, Penney RB, Yao-Borengasser A, Starlard-Davenport A, Dhakal IB, Kadlubar S.

Int J Cancer Res Mol Mech. 2015 Oct;1(3). doi: 10.16966/2381-3318.112. Epub 2015 Sep 22.

13.

Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.

Yu D, Tolleson WH, Knox B, Jin Y, Guo L, Guo Y, Kadlubar SA, Ning B.

Biochem Pharmacol. 2015 Dec 15;98(4):671-80. doi: 10.1016/j.bcp.2015.09.020. Epub 2015 Sep 30.

14.

Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Dates CR, Fahmi T, Pyrek SJ, Yao-Borengasser A, Borowa-Mazgaj B, Bratton SM, Kadlubar SA, Mackenzie PI, Haun RS, Radominska-Pandya A.

Cancer Biol Ther. 2015;16(5):714-23. doi: 10.1080/15384047.2015.1026480.

15.

Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells.

Yao-Borengasser A, Monzavi-Karbassi B, Hedges RA, Rogers LJ, Kadlubar SA, Kieber-Emmons T.

Oncol Rep. 2015 Jun;33(6):2689-94. doi: 10.3892/or.2015.3880. Epub 2015 Mar 30.

16.

Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.

Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B.

Sci Rep. 2015 Feb 23;5:8534. doi: 10.1038/srep08534.

17.

Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry.

Starlard-Davenport A, Orloff MS, Dhakal I, Penney RB, Kadlubar SA.

PLoS One. 2015 Feb 3;10(2):e0117347. doi: 10.1371/journal.pone.0117347. eCollection 2015.

18.

Pharmacogenetics of SULT1A1.

Daniels J, Kadlubar S.

Pharmacogenomics. 2014 Nov;15(14):1823-1838.

19.

Cross-sectional study to assess the association of population density with predicted breast cancer risk.

Lee JY, Klimberg S, Bondurant KL, Phillips MM, Kadlubar SA.

Breast J. 2014 Nov-Dec;20(6):615-21. doi: 10.1111/tbj.12330. Epub 2014 Sep 8.

PMID:
25200109
20.

CYP19A1 single nucleotide polymorphism associations with CYP19A1, NFκB1, and IL6 gene expression in human normal colon and normal liver samples.

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML.

Pharmgenomics Pers Med. 2014 Jul 14;7:163-71. doi: 10.2147/PGPM.S62238. eCollection 2014.

21.

A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives.

Greer AK, Dates CR, Starlard-Davenport A, Edavana VK, Bratton SM, Dhakal IB, Finel M, Kadlubar SA, Radominska-Pandya A.

Drug Metab Dispos. 2014 Sep;42(9):1392-400. doi: 10.1124/dmd.114.058016. Epub 2014 Jun 10.

22.

High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.

Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S.

Am J Clin Oncol. 2016 Jun;39(3):248-54. doi: 10.1097/COC.0000000000000046.

23.

Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells.

Yao-Borengasser A, Rogers LJ, Edavana VK, Penney RB, Yu X, Dhakal IB, Williams S, Kadlubar SA.

BMC Clin Pathol. 2014 Jan 6;14(1):1. doi: 10.1186/1472-6890-14-1.

24.

Fulvestrant up regulates UGT1A4 and MRPs through ERα and c-Myb pathways: a possible primary drug disposition mechanism.

Edavana VK, Penney RB, Yao-Borengasser A, Williams S, Rogers L, Dhakal IB, Kadlubar S.

Springerplus. 2013 Nov 20;2:620. doi: 10.1186/2193-1801-2-620. eCollection 2013.

25.

Polymorphisms of ERBB2 and breast cancer risk: a meta-analysis of 26 studies involving 35,088 subjects.

Kadlubar SA.

J Surg Oncol. 2013 Nov;108(6):335-6. doi: 10.1002/jso.23404. Epub 2013 Sep 20. No abstract available.

PMID:
24142574
26.

Lack of correlation between in silico projection of function and quantitative real-time PCR-determined gene expression levels in colon tissue.

Penney RB, Lundgreen A, Yao-Borengasser A, Koroth-Edavana V, Williams S, Wolff R, Slattery ML, Kadlubar S.

Pharmgenomics Pers Med. 2013 Sep 9;6:99-103. doi: 10.2147/PGPM.S49199. eCollection 2013.

27.

Sulfotransferase genetic variation: from cancer risk to treatment response.

Daniels J, Kadlubar S.

Drug Metab Rev. 2013 Nov;45(4):415-22. doi: 10.3109/03602532.2013.835621. Epub 2013 Sep 6. Review.

28.

Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects.

Yu X, Kubota T, Dhakal I, Hasegawa S, Williams S, Ozawa S, Kadlubar S.

Pharmgenomics Pers Med. 2013;6:19-24. doi: 10.2147/PGPM.S36579. Epub 2013 Mar 6.

29.

GSTM1 copy number and promoter haplotype as predictors for risk of recurrence and/or second primary tumor in patients with head and neck cancer.

Zhang X, Huang M, Wu X, Kadlubar S, Lin J, Yu X, Fan C, Ning B, Kadlubar FF.

Pharmgenomics Pers Med. 2013;6:9-17. doi: 10.2147/PGPM.S35949. Epub 2013 Mar 1.

30.

Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S.

Drug Metab Dispos. 2013 Apr;41(4):870-7. doi: 10.1124/dmd.112.048157. Epub 2013 Jan 31.

31.

Differential promoter activities of functional haplotypes in the 5'-flanking region of human sulfotransferase 1A1.

Lin ZN, Lin YC, Zhang X, Kadlubar S, Tuo J, Green B, Deng H, Ning B.

J Biochem Mol Toxicol. 2012 Oct;26(10):422-8. doi: 10.1002/jbt.21437.

PMID:
23080433
32.

Association between GSTM1 copy number, promoter variants and susceptibility to urinary bladder cancer.

Zhang X, Lin J, Wu X, Lin Z, Ning B, Kadlubar S, Kadlubar FF.

Int J Mol Epidemiol Genet. 2012;3(3):228-36. Epub 2012 Aug 31.

33.

Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1.

Edavana VK, Yu X, Dhakal IB, Williams S, Ning B, Cook IT, Caldwell D, Falany CN, Kadlubar S.

Pharmgenomics Pers Med. 2011 Nov 16;4:137-145.

34.

Interleukin genes and associations with colon and rectal cancer risk and overall survival.

Bondurant KL, Lundgreen A, Herrick JS, Kadlubar S, Wolff RK, Slattery ML.

Int J Cancer. 2013 Feb 15;132(4):905-15. doi: 10.1002/ijc.27660. Epub 2012 Jun 26.

35.

Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.

Rohn KJ, Cook IT, Leyh TS, Kadlubar SA, Falany CN.

Drug Metab Dispos. 2012 Aug;40(8):1588-95. doi: 10.1124/dmd.112.045583. Epub 2012 May 16.

36.

Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.

Edavana VK, Dhakal IB, Yu X, Williams S, Kadlubar S.

Drug Metab Dispos. 2012 Jun;40(6):1210-5. doi: 10.1124/dmd.111.044040. Epub 2012 Mar 20.

37.

Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells.

Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D.

BMC Cancer. 2012 Jan 20;12:29. doi: 10.1186/1471-2407-12-29.

38.

JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.

Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL, Wolff RK.

Mol Carcinog. 2013 Feb;52(2):155-66. doi: 10.1002/mc.21841. Epub 2011 Nov 28.

39.

Lack of substrate inhibition in a monomeric form of human cytosolic SULT2A1.

Cook IT, Leyh TS, Kadlubar SA, Falany CN.

Horm Mol Biol Clin Investig. 2010 Dec;3(1):357-366.

40.

Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer.

Khaidakov M, Mitra S, Kang BY, Wang X, Kadlubar S, Novelli G, Raj V, Winters M, Carter WC, Mehta JL.

PLoS One. 2011;6(5):e20277. doi: 10.1371/journal.pone.0020277. Epub 2011 May 26.

41.

Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer.

Zhang X, Zhong R, Zhang Z, Yuan J, Liu L, Wang Y, Kadlubar S, Feng F, Miao X.

Mol Carcinog. 2011 Nov;50(11):876-83. doi: 10.1002/mc.20784. Epub 2011 May 2.

PMID:
21538574
42.

Establishment of a southern breast cancer cohort.

Bondurant KL, Harvey S, Klimberg S, Kadlubar S, Phillips MM.

Breast J. 2011 May-Jun;17(3):281-8. doi: 10.1111/j.1524-4741.2011.01082.x. Epub 2011 Apr 13.

PMID:
21489034
43.

Variation in the CYP19A1 gene and risk of colon and rectal cancer.

Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK.

Cancer Causes Control. 2011 Jul;22(7):955-63. doi: 10.1007/s10552-011-9768-x. Epub 2011 Apr 11.

44.

Genetic variation in bone morphogenetic protein and colon and rectal cancer.

Slattery ML, Lundgreen A, Herrick JS, Kadlubar S, Caan BJ, Potter JD, Wolff RK.

Int J Cancer. 2012 Feb 1;130(3):653-64. doi: 10.1002/ijc.26047. Epub 2011 Apr 27.

45.

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.

Kamdem LK, Liu Y, Stearns V, Kadlubar SA, Ramirez J, Jeter S, Shahverdi K, Ward BA, Ogburn E, Ratain MJ, Flockhart DA, Desta Z.

Br J Clin Pharmacol. 2010 Dec;70(6):854-69. doi: 10.1111/j.1365-2125.2010.03791.x.

46.

Lack of substrate inhibition in a monomeric form of human cytosolic SULT2A1.

Cook IT, Leyh TS, Kadlubar SA, Falany CN.

Horm Mol Biol Clin Investig. 2010 Dec 1;3(1):367-74. doi: 10.1515/HMBCI.2010.041.

PMID:
25961208
47.

Functional genetic variants in the 3'-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity.

Yu X, Dhakal IB, Beggs M, Edavana VK, Williams S, Zhang X, Mercer K, Ning B, Lang NP, Kadlubar FF, Kadlubar S.

Toxicol Sci. 2010 Dec;118(2):391-403. doi: 10.1093/toxsci/kfq296. Epub 2010 Sep 29.

48.

Structural rearrangement of SULT2A1: effects on dehydroepiandrosterone and raloxifene sulfation.

Cook IT, Leyh TS, Kadlubar SA, Falany CN.

Horm Mol Biol Clin Investig. 2010;1(2):81-87.

49.

Expression of sulfotransferase isoform 1A1 (SULT1A1) in breast cancer cells significantly increases 4-hydroxytamoxifen-induced apoptosis.

Mercer KE, Apostolov EO, Gamboa da Costa G, Yu X, Lang P, Roberts DW, Davis W, Basnakian AG, Kadlubar FF, Kadlubar SA.

Int J Mol Epidemiol Genet. 2010 Jan 30;1(2):92-103.

50.

Phenotypic CYP2A6 variation and the risk of pancreatic cancer.

Kadlubar S, Anderson JP, Sweeney C, Gross MD, Lang NP, Kadlubar FF, Anderson KE.

JOP. 2009 May 18;10(3):263-70.

Supplemental Content

Loading ...
Support Center